At Ajanta Pharma we are proud to be among the top 25 companies in India with 25th rank in Sep 2025 as per IQVIA.
Our focus is on offering products that bring something new to the table. This approach has laid the foundation for Ajanta’s deeper involvement in specialty care. Over the past decade, we have steadily galloped ranking in India market with clear focus on 4 fast growing specialty therapeutic segments, driven by launching first of its kind innovative products in the market.
Today Ajanta holds a strong position in all the 4 major therapeutic segments of Cardiology, Dermatology, Ophthalmology and Pain Management with many of our brands enjoying leadership positions in respective sub-therapeutic segments. We have been growing faster than the industry in all these segments by accelerating access to healthcare solutions. Recently Ajanta also got into two new promising therapies of Nephrology and Gynaecology. Ajanta’s strength comes from a unique advantage of launching differentiated products ahead of competition. Out of the rich basket of 300+ products launched in India, more than 50% products are 1st to market.
In Ophthalmology segment, Ajanta has developed many formulations in the eye-drop form and introduced it for the 1st time in the country. Bimat (Anti Glaucoma), Nepaflam (Anti-inflammatory), Softdrops (Lubricant), and Olopat and Alcarex (Anti-Allergics) are some of the innovative products launched in India. Ajanta enjoys 2nd rank in Ophthalmology in India as per IQVIA Sep MAT 2025 ranking.
Ajanta has a strong presence in Dermatology with 13th rank in India as per IQVIA Sep MAT 2025. Products like Melacare cream for Melasma problem; Pacroma, the topical immune modulators; Antidandruff shampoo Salisia KT; moisturizing lotion Aquasoft are enjoying leading positions in their sub therapeutic segments.
For Cardiology segment, Ajanta has many innovative products like MET XL (1st extended-release formulation of Metoprolol), Atorfit CV (combination of Atorvastatin & Clopidogrel), Antihypertensive Cinod (Cilnidipine), Rosutor Gold (Triple combination - Aspirin, Rosuvastatin & Clopidogrel), Dapalex (SGLT 2 Inhibitor), and Vilatin (DDDP4 inhibitor). All these products are leaders in their sub-segments and have created strong brand equity with the medical professionals. We stand at 17th rank in Cardiology in India as per IQVIA MAT ranking for Sep 2025.
For Pain Management segment, Ajanta ranks 27th in India as per IQVIA MAT ranking for Sep 2025. Ajanta’s brand Feburic indicated for anti-gout therapy enjoys top position for the Febuxostat molecule.
Ajanta got into promising new segment of Nephrology, providing innovative products for every stage of kidney disease covering pre-dialysis, dialysis, and transplant. In this segment, Ajanta has introduced many innovative products like Renagold DS, Dabanox, Fumac, Tocyl, Phenolac S, and Valpose.
In Gynaecology, Ajanta has introduced products like Amgest, Apcor, Caltuf, Dagiran, Fedate, Menoroz, Poliquin, and Spazio. The portfolio is tailored to manage various gynaecological conditions, including Polycystic Ovary Syndrome (PCOS), endometriosis, threatened abortions, and recurrent pregnancy loss.
